This site is intended for healthcare
professionals in Belgium and Luxembourg.
MECHANISM OF ACTION
Reblozyl® addresses ineffective late-stage erythropoiesis by promoting erythroid maturation1-3
Reblozyl® is a recombinant fusion protein that binds selected TGF-β superfamily ligands to reduce Smad 2/3 signaling, which is abnormally high in disease models characterized by ineffective erythropoiesis, (ie, MDS and β-thalassemia).1-3
Reblozyl® is the first and only erythroid maturation agent1
Reblozyl® addresses ineffective late-stage erythropoiesis by promoting erythroid maturation1-3
Reblozyl® is the first and only erythroid maturation agent1
Reblozyl® is a recombinant fusion protein that binds selected TGF-β superfamily ligands to reduce Smad 2/3 signaling, which is abnormally high in disease models characterized by ineffective erythropoiesis, (ie, MDS and β-thalassemia).1-3
Reblozyl® is the first and only erythroid maturation agent1
Reblozyl® is a recombinant fusion protein that binds selected TGF-β superfamily ligands to reduce Smad 2/3 signaling, which is abnormally high in disease models characterized by ineffective erythropoiesis, (ie, MDS and β-thalassemia).1-3